Joseph P. Wagner
Chief Scientific OfficerDr. Joseph P. Wagner, Ph.D., serves as a Chief Development Officer at Modulo Bio, Inc. from July 2025. He serves as Chief Scientific Officer at Notable Labs, Inc., since July 2020 and served as its Interim Chief Executive Officer from August 26, 2024 to September 16, 2024. Dr. Wagner served as the Chief Executive Officer and President of BriaCell Therapeutics Corp. from June 1, 2015 to March 24, 2016. Dr. Wagner served as the Chief Executive Officer at OncoCyte Corporation until May 29, 2015. He served as a Vice President of Cellular Therapy at Garnet Biotherapeutics Inc. (Also Known As: Neuronyx, Inc.). He served as Senior Director of Cell Biology and Research & Development at Garnet Biotherapeutics, Inc. He served as the President and Chief Technology Officer at Cell Targeting, Inc. (CTI), responsible for all corporate functions including all R&D, Finance and Corporate Development. He served as a Director of BriaCell Therapeutics Corp. from June 1, 2015 to March 24, 2016. He was an Associate Professor at the Karolinska Institute, where his research focused on molecular and cellular approaches to brain development. Dr. Wagner holds a B.S. in Neuroscience from the University of Rochester and received his Ph.D. in Pharmacology from Duke University. Dr. Wagner was a Postdoctoral Fellow in the Department of Neuroscience and Cell Biology at the Robert W. Johnson Medical School.
Positions
- Company NameNotable Labs, Ltd.Stock CodeNTBLQPositionChief Scientific OfficerColleagues
- SAScott Alan McPhersonChief Financial Officer
- TPTuomo PatsiIndependent Chairman
- KZKaile ZaggerInterim CEO & Chief Restructuring Officer
- GCGlenn C. MichelsonChief Medical Officer
- TIThomas I. H. DubinIndependent External Director
- TGThomas GraneyIndependent External Director
- PFPeter FeinbergIndependent Director
- MGMichele GalenIndependent Director
